Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Drug: Placebo
- Registration Number
- NCT03985943
- Lead Sponsor
- Galderma R&D
- Brief Summary
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.
- Detailed Description
This was a randomized, double-blind, placebo-controlled, multi-center, parallel-group study in adult and adolescent subjects of age 12 years and above with moderate-to-severe AD. Eligible subjects had a documented history of inadequate response to topical AD medication(s). Approximately 750 subjects were randomized in 2:1 to receive either nemolizumab or placebo, stratified by baseline disease severity (Investigator's Global Assessment (IGA) = 3, moderate; IGA = 4, severe) and peak pruritus numeric rating scale (PP NRS) severity (PP NRS \>= 7; PP NRS \< 7). A minimum of 250 subjects were randomized in each PP NRS strata. All nemolizumab-treated subjects who were clinical responders at Week 16 (i.e., the end of initial treatment \[Initial Treatment Period\]/beginning of Maintenance Period) were re-randomized (1:1:1) to different treatment regimens (nemolizumab injections Q4W or every 8 weeks (Q8W) \[with placebo injections at Weeks 20, 28, 36, and 44 to maintain the blind\] or placebo Q4W). A clinical responder was defined as a subject at Week 16 with an IGA of 0 (clear) or 1 (almost clear) or a \>= 75% improvement in EASI from baseline (EASI-75). All placebo-treated subjects who responded to placebo during the Initial Treatment Period continued to receive placebo Q4W in the Maintenance Period.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 941
- Male or female subjects aged greater than and equal to (>=) 12 years at the screening visit.
- Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for at least 2 years before the screening visit.
- Eczema Area and Severity Index (EASI) score >=16 at the screening and baseline visits.
- Investigator Global Assessment (IGA) score >= 3 (scale of 0 to 4) at the screening and baseline visits.
- AD involvement >= 10 percent (%) of body surface area (BSA) at screening and baseline visits.
- Peak Pruritus Numerical Rating Scale (PPNRS) score of at least 4.0 at the screening and baseline visit.
- Documented recent history of inadequate response to topical medications (topical corticosteroids [TCS] with or without Topical calcineurin inhibitors [TCI]).
- Female subjects of childbearing potential (that is, fertile, following menarche and until becoming postmenopausal unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection, or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection.
Key
- Body weight (<) 30 kilograms (kg).
- Exacerbation of asthma requiring hospitalization in the preceding 12 months. Uncontrolled asthma in the preceding 3 months.
- Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 2 weeks before the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit.
- Pregnant women, breastfeeding women, or women planning a pregnancy during the clinical study.
Note: Subjects with chronic, stable use of prophylactic treatment for recurrent herpes viral infection can be included in this clinical study.
- History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, example, monoclonal antibody) or to any of the study drug excipients.
- Any clinically significant issue, based on investigator judgement.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Placebo Nemolizumab Nemolizumab Nemolizumab Active
- Primary Outcome Measures
Name Time Method Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus Population Week 16 IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of AD and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered a treatment failure. Participants with missing data at Week 16 were considered non-responders.
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population Week 16 EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD(erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD.
Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population Week 16 IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of atopic dermatitis (AD) and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders.
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus Population Week 16 EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population Week 16 The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population Week 16 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population Week 16 The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population Week 16 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population Week 16 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: ITT Population Week 2 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population Week 16 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: Severe Pruritus Population Week 4 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: Severe Pruritus Population Week 1 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: ITT Population Week 4 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: ITT Population Week 4 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: Severe Pruritus Population Week 4 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: ITT Population Week 1 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: Severe Pruritus Population Week 2 The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.
Trial Locations
- Locations (174)
Galderma Investigational Site 8336
🇨🇦Toronto, Ontario, Canada
Galderma Investigational Site 8882
🇺🇸Bangor, Maine, United States
Galderma Investigational Site 6243
🇵🇱Gdańsk, Poland
Galderma Investigational Site 6065
🇵🇱Warszawa, Poland
Galderma Investigational Site 6242
🇵🇱Warszawa, Poland
Galderma Investigational Site 6222
🇵🇱Warszawa, Poland
Galderma Investigational Site 5005
🇵🇱Wrocław, Poland
Galderma Investigational Site 6245
🇵🇱Łódź, Poland
Galderma Investigational Site 8042
🇺🇸Houston, Texas, United States
Galderma Investigational Site 8710
🇺🇸Miami, Florida, United States
Galderma Investigational Site 8801
🇺🇸Miami, Florida, United States
Galderma Investigational Site 8737
🇺🇸Miami, Florida, United States
Galderma Investigational Site 8708
🇺🇸Miami, Florida, United States
Galderma Investigational Site 8686
🇺🇸Lomita, California, United States
Galderma Investigational Site 8880
🇺🇸North Little Rock, Arkansas, United States
Galderma Investigational Site 8888
🇺🇸Fullerton, California, United States
Galderma Investigational Site 8636
🇺🇸Fountain Valley, California, United States
Galderma Investigational Site 8255
🇺🇸Philadelphia, Pennsylvania, United States
Galderma Investigational Site 8206
🇺🇸Norman, Oklahoma, United States
Galderma Investigational Site 8664
🇺🇸Frisco, Texas, United States
Galderma Investigational Site 8608
🇺🇸Santa Monica, California, United States
Galderma Investigational Site 8595
🇺🇸Dublin, Ohio, United States
Galderma Investigational Site 8897
🇺🇸Brandon, Florida, United States
Galderma Investigational Site 8818
🇺🇸Rapid City, South Dakota, United States
Galderma Investigational Site 8279
🇺🇸New York, New York, United States
Galderma Investigational Site 8620
🇺🇸New York, New York, United States
Galderma Investigational Site 8728
🇺🇸Newnan, Georgia, United States
Galderma Investigational Site 8802
🇺🇸Plymouth Meeting, Pennsylvania, United States
Galderma Investigational Site 8806
🇺🇸Miami Lakes, Florida, United States
Galderma Investigational Site 8887
🇺🇸Union City, Georgia, United States
Galderma Investigational Site 8648
🇺🇸Wilmington, North Carolina, United States
Galderma Investigational Site 6194
🇦🇹Vienna, Wien, Austria
Galderma Investigational Site 6108
🇳🇱Rotterdam, Netherlands
Galderma Investigational Site 6027
🇳🇱Utrecht, Netherlands
Galderma Investigational Site 6255
🇵🇱Czestochowa, Poland
Galderma Investigational Site 6071
🇵🇱Lublin, Poland
Galderma Investigational Site 6064
🇵🇱Warszawa, Poland
Galderma Investigational Site 6024
🇨🇿Prague, Czechia
Galderma Investigational Site 8780
🇨🇦Niagara Falls, Canada
Galderma Investigational Site 6212
🇳🇱Groningen, Netherlands
Galderma Investigational Site 5138
🇵🇱Gdańsk, Poland
Galderma Investigational Site 6244
🇵🇱Gdynia, Poland
Galderma Investigational Site 6237
🇵🇱Ostrowiec Świętokrzyski, Poland
Galderma Investigational Site 6061
🇩🇪Bielefeld, Germany
Galderma Investigational Site 6118
🇳🇿Wellington, New Zealand
Galderma Investigational Site 8610
🇨🇦Ottawa, Canada
Galderma Investigational Site 6035
🇪🇸Barcelona, Spain
Galderma Investigational Site 6066
🇩🇪Buxtehude, Germany
Galderma Investigational Site 6075
🇵🇱Gdańsk, Poland
Galderma Investigational Site 6047
🇵🇱Wrocław, Poland
Galderma Investigational Site 6022
🇩🇪Bad Bentheim, Germany
Galderma Investigational Site 5437
🇩🇪Kiel, Schleswig-Holst, Germany
Galderma Investigational Site 6204
🇬🇧Liverpool, United Kingdom
Galderma Investigational Site 6087
🇵🇱Katowice, Poland
Galderma Investigational Site 6127
🇵🇱Poznań, Poland
Galderma Investigational Site 6223
🇵🇱Szczecin, Poland
Galderma Investigational Site 6122
🇵🇱Warszawa, Poland
Galderma Investigational Site 6104
🇬🇧Glasgow, United Kingdom
Galderma Investigational Site 6119
🇳🇿Hamilton, New Zealand
Galderma Investigational Site 6057
🇪🇸Alicante, Spain
Galderma Investigational Site 5842
🇪🇸Madrid, Spain
Galderma Investigational Site 6231
🇵🇱Łódź, Poland
Galderma Investigational Site 6106
🇪🇸Las Palmas De Gran Canaria, Spain
Galderma Investigational Site 5580
🇪🇸Barcelona, Spain
Galderma Investigational Site 6206
🇬🇧Stockton-on-Tees, United Kingdom
Galderma Investigational Site 5570
🇵🇱Łódź, Poland
Galderma Investigational Site 6058
🇪🇸Madrid, Spain
Galderma Investigational Site 6190
🇪🇸Madrid, Spain
Galderma Investigational Site 6037
🇪🇸Barcelona, Spain
Galderma Investigational Site 6205
🇬🇧Manchester, United Kingdom
Galderma Investigational Site 6202
🇬🇧Barnsley, United Kingdom
Galderma Investigational Site 6203
🇬🇧Cannock, United Kingdom
Galderma Investigational Site 8857
🇺🇸Oklahoma City, Oklahoma, United States
Galderma Investigational Site 6036
🇪🇸Madrid, Spain
Galderma Investigational Site 5551
🇪🇸Madrid, Spain
Galderma Investigational Site 6121
🇬🇧London, United Kingdom
Galderma Investigational Site 6191
🇪🇸Pamplona, Spain
Galderma Investigational Site 8578
🇺🇸Cerritos, California, United States
Galderma Investigational Site 8674
🇺🇸Los Angeles, California, United States
Galderma Investigational Site 8125
🇺🇸San Francisco, California, United States
Galderma Investigational Site 8895
🇺🇸Santa Ana, California, United States
Galderma Investigational Site 8711
🇺🇸Jacksonville, Florida, United States
Galderma Investigational Site 8805
🇺🇸Cape Coral, Florida, United States
Galderma Investigational Site 8902
🇺🇸Doral, Florida, United States
Galderma Investigational Site 8804
🇺🇸Hialeah, Florida, United States
Galderma Investigational Site 8800
🇺🇸Miami Lakes, Florida, United States
Galderma Investigational Site 8744
🇺🇸Macon, Georgia, United States
Galderma Investigational Site 8734
🇺🇸Pembroke Pines, Florida, United States
Galderma Investigational Site 8890
🇺🇸Blackfoot, Idaho, United States
Galderma Investigational Site 8571
🇺🇸Skokie, Illinois, United States
Galderma Investigational Site 8819
🇺🇸Nampa, Idaho, United States
Galderma Investigational Site 8712
🇺🇸Skokie, Illinois, United States
Galderma Investigational Site 8142
🇺🇸Indianapolis, Indiana, United States
Galderma Investigational Site 8155
🇺🇸Troy, Michigan, United States
Galderma Investigational Site 8512
🇺🇸Bay City, Michigan, United States
Galderma Investigational Site 8748
🇺🇸Ypsilanti, Michigan, United States
Galderma Investigational Site 8521
🇺🇸Saint Joseph, Missouri, United States
Galderma Investigational Site 8740
🇺🇸Henderson, Nevada, United States
Galderma Investigational Site 8810
🇺🇸Omaha, Nebraska, United States
Galderma Investigational Site 8718
🇺🇸Missoula, Montana, United States
Galderma Investigational Site 8242
🇺🇸Brooklyn, New York, United States
Galderma Investigational Site 8702
🇺🇸Bexley, Ohio, United States
Galderma Investigational Site 8238
🇺🇸Dallas, Texas, United States
Galderma Investigational Site 8133
🇺🇸Arlington, Texas, United States
Galderma Investigational Site 8827
🇺🇸Dripping Springs, Texas, United States
Galderma Investigational Site 8862
🇺🇸Fairfax, Virginia, United States
Galderma Investigational Site 5441
🇦🇺Darlinghurst, New South Wales, Australia
Galderma Investigational Site 6152
🇦🇺Westmead, New South Wales, Australia
Galderma Investigational Site 5759
🇦🇺Kogarah, New South Wales, Australia
Galderma Investigational Site 5638
🇦🇺Benowa, Queensland, Australia
Galderma Investigational Site 6161
🇦🇺Brisbane, Queensland, Australia
Galderma Investigational Site 6131
🇦🇺Carlton, Victoria, Australia
Galderma Investigational Site 5366
🇦🇺East Melbourne, Victoria, Australia
Galderma Investigational Site 6159
🇦🇺Woodville, South Australia, Australia
Galderma Investigational Site 6153
🇦🇺Victoria Park, Western Australia, Australia
Galderma Investigational Sites 6157
🇦🇹Graz, Styria, Austria
Galderma Investigational Site 5458
🇦🇺Parkville, Victoria, Australia
Galderma Investigational Site 5453
🇦🇺Fremantle, Western Australia, Australia
Galderma Investigational Site 6158
🇦🇹Vienna, Austria
Galderma Investigational Site 8085
🇨🇦Calgary, Alberta, Canada
Galderma Investigational Site 8903
🇨🇦Calgary, Alberta, Canada
Galderma Investigational Site 8215
🇨🇦Calgary, Alberta, Canada
Galderma Investigational Site 8161
🇨🇦Surrey, British Columbia, Canada
Galderma Investigational Site 8586
🇨🇦Barrie, Ontario, Canada
Galderma Investigational Site 8901
🇨🇦Ottawa, Ontario, Canada
Galderma Investigational Site 8904
🇨🇦Guelph, Ontario, Canada
Galderma Investigational Site 8899
🇨🇦Toronto, Ontario, Canada
Galderma Investigational Site 8000
🇨🇦Saint John, Canada
Galderma Investigational Site 5225
🇨🇿Náchod, Czechia
Galderma Investigational Site 6054
🇨🇿Praha, Czechia
Galderma Investigational Site 6240
🇨🇿Prague, Czechia
Galderma Investigational Site 6055
🇨🇿Brno, Czechia
Galderma Investigational Site 8731
🇨🇦Waterloo, Canada
Galderma Investigational Site 6030
🇨🇿Olomouc, Czechia
Galderma Investigational Site 6021
🇨🇿Praha, Czechia
Galderma Investigational Site 6025
🇨🇿Praha, Czechia
Galderma Investigational Site 6172
🇩🇪Berlin, NRW, Germany
Galderma Investigational Site 6214
🇩🇪Tuebingen, Niedersachesen, Germany
Galderma Investigational Site 6146
🇩🇪Langenau, Hesse, Germany
Galderma Investigational Site 6110
🇩🇪Berlin, Germany
Galderma Investigational Site 5368
🇩🇪Darmstadt, Germany
Galderma Investigational Site 6028
🇩🇪Dülmen, Germany
Galderma Investigational Site 5918
🇩🇪Osnabrück, Germany
Galderma Investigational Site 6039
🇩🇪Münster, Germany
Galderma Investigational Site 6154
🇰🇷Gyeonggi-do, Korea, Republic of
Galderma Investigational Site 6109
🇩🇪Stuttgart, Germany
Galderma Investigational Site 6095
🇰🇷Bucheon, Korea, Republic of
Galderma Investigational Site 6100
🇰🇷Busan, Korea, Republic of
Galderma Investigational Site 6094
🇰🇷Seoul, Korea, Republic of
Galderma Investigational Site 6098
🇰🇷Gyeonggi-do, Korea, Republic of
Galderma Investigational Site 6138
🇰🇷Incheon, Korea, Republic of
Galderma Investigational Site 6120
🇰🇷Incheon, Korea, Republic of
Galderma Investigational Site 6093
🇰🇷Incheon, Korea, Republic of
Galderma Investigational Site 5659
🇰🇷Seoul, Korea, Republic of
Galderma Investigational Site 6105
🇰🇷Seoul, Korea, Republic of
Galderma Investigational Site 6116
🇰🇷Seoul, Korea, Republic of
Galderma Investigational Site 6129
🇰🇷Seoul, Korea, Republic of
Galderma Investigational Site 6103
🇰🇷Seoul, Korea, Republic of
Galderma Investigational Site 6056
🇰🇷Seoul, Korea, Republic of
Galderma Investigational Site 6113
🇱🇻Liepāja, Latvia
Galderma Investigational Site 6134
🇱🇻Riga, Latvia
Galderma Investigational Site 6059
🇱🇻Riga, Latvia
Galderma Investigational Site 6060
🇱🇻Talsi, Latvia
Galderma Investigational Site 6072
🇱🇹Klaipėda, Lithuania
Galderma Investigational Site 6112
🇱🇹Vilnius, Lithuania
Galderma Investigational Site 6111
🇱🇹Kaunas, Lithuania
Galderma Investigational Site 6207
🇬🇧Blackpool, United Kingdom
Galderma Investigational Site 6099
🇰🇷Seoul, Korea, Republic of
Galderma Investigational Site 8771
🇺🇸Louisville, Kentucky, United States
Galderma Investigational Site 8743
🇺🇸Ann Arbor, Michigan, United States
Galderma Investigational Site 8736
🇺🇸Charleston, South Carolina, United States
Galderma Investigational Site 8088
🇨🇦Edmonton, Alberta, Canada
Galderma Investigational Site 8824
🇨🇦Edmonton, Alberta, Canada
Galderma Investigational Site 8722
🇨🇦Edmonton, Alberta, Canada